BioGenCell’s mission is to develop an innovative technology platform that will enable the rapid creation of easy-to-use and cost-effective treatments for a wide range of degenerative diseases using highly standardized therapies derived from adult stem cells.
Marc Dechamps is a biologist with extensive experience of more than 30 years in the Pharmaceutical industry, with expertise in market development for new products including infectious diseases, immunological disorders, cancer, CNS diseases and vaccines. He started his career with sales and marketing management positions at corporate pharma companies including Glaxo, Glaxo Wellcome and GSK. His last position was Executive Director of the Commercial department “Specialty care & Vaccines” at GSK . In 2009 he became Head of the European Mid-Size Countries Region at ViiV Healthcare (ViiVHC), a spin out company created by GSK and Pfizer where he created and managed 4 ViiVHC Companies and built a European Commercial – Market Access Operations team dedicated to the launch of the new assets of ViiVHC. Since 2016 Mr. Dechamps has supported biotechnological start-up companies in the field of gene and cell therapies with strategic advising and management leadership. Before joining BioGenCell Marc served as Managing Director of Delphi Genetics, a Belgian Biotech company specialised in the production of plasmid DNA. Marc is also currently acting as Chairman of the Management Committee of eTheRNA, a “round A” Belgian biotech company, involved in Immuno-oncology, developing a specific mRNA platform for boosting the immune system.